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Abstract
Background:  Complicated intra-abdominal infections (cIAI) remain challenging to treat because of their
polymicrobial etiology including multi-drug resistant bacteria. The efficacy and safety of tigecycline, an expanded
broad-spectrum glycylcycline antibiotic, was compared with imipenem/cilastatin (IMI/CIS) in patients with cIAI.
Methods: A prospective, double-blind, multinational trial was conducted in which patients with cIAI randomly
received intravenous (IV) tigecycline (100 mg initial dose, then 50 mg every 12 hours [q12h]) or IV IMI/CIS (500/
500 mg q6h or adjusted for renal dysfunction) for 5 to14 days. Clinical response at the test-of-cure (TOC) visit
(14–35 days after therapy) for microbiologically evaluable (ME) and microbiological modified intent-to-treat (m-
mITT) populations were the co-primary efficacy endpoint populations.
Results: A total of 825 patients received ≥ 1 dose of study drug. The primary diagnoses for the ME group were
complicated appendicitis (59%), and intestinal (8.8%) and gastric/duodenal perforations (4.6%). For the ME group,
clinical cure rates at TOC were 80.6% (199/247) for tigecycline versus 82.4% (210/255) for IMI/CIS (95% CI -8.4,
5.1 for non-inferiority tigecycline versus IMI/CIS). Corresponding clinical cure rates within the m-mITT population
were 73.5% (227/309) for tigecycline versus 78.2% (244/312) for IMI/CIS (95% CI -11.0, 2.5). Nausea (31.0%
tigecycline, 24.8% IMI/CIS [P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [P = 0.037]), and diarrhea
(21.3% tigecycline, 18.9% IMI/CIS [P = 0.435]) were the most frequently reported adverse events.
Conclusion: This study demonstrates that tigecycline is as efficacious as imipenem/cilastatin in the treatment of
patients with cIAI.
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Background
Complicated intra-abdominal infections are characterized
as local or systemic infections secondary to a physical per-
foration in the gastrointestinal tract or via a necrotic gut
wall into the peritoneal space, leading to abscess forma-
tion or peritonitis [1]. These infections require a combina-
tion of appropriate and timely surgical source control and
broad spectrum antimicrobial therapy for optimal out-
come. Nearly all intra-abdominal infections are caused by
multiple microorganisms resident in the gastrointestinal
tract; these include aerobes and facultative and obligate
anaerobes [2], with Enterobacteriaceae (eg, Escherichia
coli) isolated most frequently [1,3]. Although isolation of
enterococci from an intra-abdominal source were once
suggestive of normal flora, these bacteria are now recog-
nized as true pathogens, with upwards of one third of
intra-abdominal cultures yielding enterococci [2]. In fact,
the isolation of Enterococcus spp. from an intra-abdominal
focus of infection has been linked with treatment failure
[4].
Treatment of complicated intra-abdominal infections
remains a challenge, primarily because of their polymicro-
bial etiology coupled with the high risk of complications
and death. Because frequently recovered isolates may pos-
sess multiple resistance factors (eg, extended spectrum
beta-lactamases [ESBLs]) that express antimicrobial resist-
ance, empiric antimicrobial therapy should have antici-
pated activity against these difficult-to-treat isolates [1,5].
As such, combination antibiotic therapy has often been a
standard of care for treatment of these infections [1]. The
recent 2003 guidelines of the Infectious Diseases Society
of America (IDSA) advocates broad-spectrum single or
combination therapy (eg, carbapenem or piperacillin/
tazobactam monotherapy, third- or fourth-generation
cephalosporins or fluoroquinolones plus metronidazole)
for high-risk patients with severe or postoperative nosoco-
mial intra-abdominal infections wherein polymicrobial
infection and/or resistant flora are more prevalent [1].
When very resistant bacteria are suspected (eg, vancomy-
cin-resistant Enterococcus, methicillin-resistant Staphylococ-
cus aureus, Pseudomonas aeruginosa), however, a complex
multidrug regimen is recommended [1]. The initial selec-
tion of antimicrobial therapy for treatment of intra-
abdominal infections is extremely important because
inappropriate empiric antimicrobial therapy has been
associated with delayed clinical resolution, increased
length of hospital stay, and an increased risk of mortality
[6,7]. Adequate surgical source control is also an impor-
tant determinant of outcome; insufficient drainage and
repair may compromise the effectiveness of antibiotic
therapy [1].
Tigecycline is a novel, first-in-class, glycylcycline antibi-
otic with expanded broad-spectrum wide in vitro activity
against the microorganisms commonly encountered in
intra-abdominal infections. Specifically, tigecycline's
spectrum of in vitro activity includes aerobic and faculta-
tive gram-positive and gram-negative bacteria and anaer-
obic bacteria [8-11]. Tigecycline also provides in vitro
activity against antibiotic-resistant bacteria such as vanco-
mycin-resistant Enterococcus faecalis and E. faecium, ESBL-
producing enteric gram-negative bacteria, and methicil-
lin-resistant S. aureus [8-16]. The primary objective of this
multicenter trial was to evaluate the efficacy and safety of
tigecycline monotherapy compared with imipenem/cilas-
tatin in the treatment of hospitalized adult patients with
complicated intra-abdominal infections. A second goal of
the study was to evaluate the in vitro susceptibility of tige-
cycline against common bacteria implicated as causes of
intra-abdominal infection.
Methods
Study design and enrollment criteria
This was a phase 3, multicenter, double-blind (third-party
unblinded) trial of adult patients who were candidates for
or had undergone a laparotomy, laparoscopy, or percuta-
neous drainage of an intra-abdominal abscess and had a
known or suspected diagnosis of complicated intra-
abdominal infection. All patients were hospitalized at the
time of study entry. Before screening of the first patient,
the protocol was reviewed and approved by the institu-
tional review board or ethical review committee at each
participating center. Written informed consent was
obtained from each patient or his or her legal representa-
tive before the start of any study procedures. The trial was
conducted in accordance with the Declaration of Helsinki.
Inclusion criteria
Men and women were eligible for inclusion if they were
18 years of age or older and required a surgical procedure
for a complicated intra-abdominal infection. Compli-
cated intra-abdominal infections included conditions
such as an intra-abdominal abscess (including liver and
spleen) that developed in a postsurgical patient after
receiving standard antibacterial therapy (ie, at least 48
hours, but note more than 5 days of antibiotics); appen-
dicitis complicated by perforation and/or a periappendi-
ceal abscess; perforated diverticulitis complicated by
abscess formation or fecal contamination; complicated
cholecystitis with evidence of perforation, empyema, or
gangrene; perforation of a gastric or duodenal ulcer with
symptoms exceeding 24 hours; purulent peritonitis or
peritonitis associated with fecal contamination; or perfo-
ration of the large or small intestine with abscess or fecal
contamination. In addition, patients could not have
received more than 1 dose of an antibiotic (single broad-
spectrum agent or 1 dose of each antibiotic in a combina-
tion regimen such as metronidazole, ampicillin,BMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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gentamicin) after the baseline intra-abdominal culture
was obtained from the infected site.
Exclusion criteria
Patients were not allowed to participate if they had any
concomitant condition that precluded evaluation of a
response or made it unlikely that the planned course of
therapy could be completed. Other primary reasons for
ineligibility included the following: preoperative suspi-
cion of a diagnosis of spontaneous bacterial peritonitis,
simple cholecystitis, gangrenous cholecystitis without
rupture, simple appendicitis, acute suppurative cholangi-
tis, pancreatic abscess, or infected necrotizing pancreatitis;
Acute Physiologic and Chronic Health Evaluation
(APACHE) II score greater than 30; active or treated leuke-
mia or systemic malignancy within the prior 3 months or
metastatic malignancy to the abdomen within the prior 6
months; known acquired immunodeficiency syndrome
(AIDS); presence of any uncontrolled central nervous sys-
tem disease; pregnant or breastfeeding women; known or
suspected hypersensitivity to either study drug or to
related compounds; concomitant ganciclovir therapy; sig-
nificant hepatic disease (ie, aspartate aminotransferase
[AST] or alanine aminotransferase [ALT] level > 10 times
the upper limit of normal [ULN] or total bilirubin value >
3 times the ULN) or acute hepatic failure or acute decom-
pensation of chronic hepatic failure; significant renal dis-
ease (ie, calculated creatinine clearance < 41 mL/min/1.73
m2 after adequate hydration); neutropenia with absolute
neutrophil count < 1000/mm3, with counts as low as 500/
mm3 permitted if due to the acute infectious process; cur-
rent intra-abdominal infection known to be caused by
one or more bacterial isolates not susceptible to either of
the study drugs (eg, P. aeruginosa, Proteus mirabilis); surgi-
cal procedure requiring that fascia or deep muscular layers
be left open or expectation of planned abdominal re-
exploration either in or out of the operating room; and
administration of intraoperative antibacterial irrigants or
peritoneal antibacterial agents (eg, irrigants, antibiotic-
impregnated sponges). Any patient requiring additional
systemic antibacterial therapy, for any reason, was not
allowed to participate in the trial.
Antimicrobial regimens
Patients were stratified at randomization into 2 groups
based on their scores on APACHE II: ≤15, or >15 but <31.
Using a 1:1 ratio, patients were randomly assigned to
receive either tigecycline (initial 100-mg dose given by
intravenous [IV] infusion over a 30-minute period, fol-
lowed by 50 mg IV every 12 hours) or IV imipenem/cilas-
tatin (500 mg/500 mg every 6 hours or dose-adjusted
based on weight and creatinine clearance). Patients rand-
omized to tigecycline received a 100 mL normal saline
intravenous infusion 6 hours after active drug each day in
order to maintain the blind. Unless the patient was a clin-
ical failure (see definition below), the duration of study
drug therapy ranged from 5 to 14 days.
Study drug was administered only when there was a
strong suspicion (ie, elevated white blood cell count, ele-
vated band cell counts [ie, evidence of a "shift to the left"],
fever, or highly suggestive radiographic findings) or a con-
firmed diagnosis of an intra-abdominal infection (pres-
ence of pus within the abdominal cavity), and a baseline
intra-abdominal culture was obtained from the site of
infection. Patients could be enrolled before drainage of
the intra-abdominal infection and may have received up
to 2 doses of study drug before the baseline cultures were
obtained. Patients did not receive more than 1 dose (or
combination) of parenteral nonstudy antibacterial drugs
after the baseline intra-abdominal cultures were obtained.
However, wound irrigation solutions of sterile water or
normal saline and topical antiseptics were permitted
throughout the course of the study.
Clinical evaluations
The clinical status of the intra-abdominal infection was
assessed at serial visits throughout the study by the pres-
ence or absence of the following signs and symptoms:
fever; localized or diffuse abdominal wall rigidity or
involuntary guarding; abdominal tenderness or pain;
ileus or hypoactive bowel sounds; nausea or vomiting.
The clinical response to study drug was determined by the
investigator. At the test-of-cure visit (14–35 days after
therapy), each patient's response was categorized as one
of the following: Cure – the course of study drug and the
initial intervention (operative and/or radiologically
guided drainage procedure) resolved the intra-abdominal
infectious process; Failure  – the patient required addi-
tional antibacterial therapy other than the study drug, the
patient required additional surgical or radiologic inter-
vention to cure the infection, death due to infection
occurred after 48 hours of therapy, the patient received an
extended course of study drug (ie, >120% of the planned
number of doses), or the patient was prematurely discon-
tinued from study drug due to an adverse event (after
receiving at least 8 doses in 5 days) and required addi-
tional antibiotic therapy or surgical intervention; and
Indeterminate – the patients was lost to follow-up, or died
within 48 hours after the first dose of study drug for any
reason, or died after 48 hours because of noninfectious-
related reasons (as judged by the investigator).
Microbiologic evaluations
Baseline aerobic and anaerobic cultures from the primary
intra-abdominal site of infection and two sets of blood
cultures were obtained within 24 hours of the first dose of
study drug. All aerobic and anaerobic bacterial isolates,
regardless of the source of cultured material, were identi-
fied and tested at a central laboratory (Covance CentralBMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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Laboratory Services, Inc., Indianapolis, IN, or Geneva,
Switzerland) by using a standard procedure approved by
the National Committee of Clinical Laboratory Standards
(NCCLS) Subcommittee on Antimicrobial Susceptibility
Testing. For tigecycline, provisional minimum inhibitory
concentration (MIC) breakpoints were used (susceptible
≤2 mg/L; intermediate 4 mg/L; resistant ≥8 mg/L).
Based on the results of the baseline intra-abdominal cul-
ture, the susceptibilities of identified organisms, and the
clinical outcome of the patient, the investigator also deter-
mined the microbiologic response at the patient level and
at the isolate level. Microbiologic response by patient was
categorized at the test-of-cure visit as eradication, persist-
ence, superinfection (ie, the emergence of a new isolate
was documented at the site of infection with worsening
signs and symptoms of infection). The microbiologic
response for each baseline isolate at the test-of-cure visit
was described according to the following definitions:
eradication, persistence, or indeterminate. Because many
patients did not have follow-up cultures, many microbio-
logic responses both at the patient and isolate level were
categorized as either presumed eradication or presumed
persistence.
Safety/tolerability assessments
All patients who received at least one dose of study drug
were evaluated for safety (modified intent-to-treat [mITT]
population). Safety was assessed from serial medical his-
tory and physical examinations, reports of clinical adverse
events, and findings from routine electrocardiograms
(ECGs), and serum chemistry, hematology, coagulation,
and urinalysis tests. Adverse events were recorded
throughout the study period, up to and including the test-
of-cure visit. Before unblinding, the investigator catego-
rized the severity of each adverse event and the potential
for relationship to study drug. Serious adverse events (ie,
those that were life-threatening, led to prolongation of the
existing hospitalization, caused persistent or significant
disability or incapacity, or death) were also recorded.
Analysis populations
Several subpopulations of patients were assessed for
safety, clinical, and bacteriologic outcomes. Patients who
satisfied the inclusion/exclusion criteria were included in
the intent-to-treat (ITT) population, whereas the subset of
patients who received at least 1 dose of study drug made
up the mITT population. Those patients in the mITT pop-
ulation who had clinical evidence of a complicated intra-
abdominal infection, by meeting the minimal disease cri-
teria, and had a confirmed baseline isolate made up the
microbiological-modified (m-mITT) population. From
this latter group, the microbiologically evaluable (ME)
population was defined as those who met all inclusion/
exclusion criteria; had at least 5 days of therapy; did not
receive concomitant antibiotics after the baseline intra-
abdominal culture was obtained through the test-of-cure
visit; had a test-of-cure visit 14 to 35 days after the first
dose of study drug; and had a baseline intra-abdominal
culture containing at least one causative isolate that was
susceptible to both study drugs. If these criteria were not
met at any time during the study, the patient was declared
non-evaluable and the outcome of cure/failure/indeter-
minate was analyzed within the m-mITT population.
Patients were considered nonevaluable for inclusion in
the ME population if death occurred or if they withdrew
from the study <48 hours after the first dose of study drug.
Statistical analysis
The primary endpoints of the study were clinical response
at the test-of-cure visit (14–35 days after therapy) for the
m-mITT and ME populations. Secondary analyses
included bacteriologic response at the test-of cure visit by
patient and isolate, as well as clinical response rates strat-
ified as monomicrobial versus polymicrobial, and by
isolate.
Patient disposition and analysis population Figure 1
Patient disposition and analysis population.BMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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Statistical analysis was performed by the Clinical Biosta-
tistics department of Wyeth Research, Collegeville, PA.
Categorical baseline demographic and medical variables
were analyzed using the Fisher exact test. Continuous var-
iables were compared using a one-way analysis of variance
(ANOVA) model with treatment as a factor. Between-
group comparisons of adverse events were analyzed by
using the Fisher exact test. For laboratory tests, vital signs,
and ECG results, within-group changes from baseline
were analyzed by using a paired t-test and between-group
comparisons were made by using the analysis of covari-
ance, adjusting for baseline value. The difference between
treatment groups in the percentage of premature with-
drawal from study drug was evaluated by using a 2-sided
Fisher exact test.
The noninferiority efficacy of tigecycline compared with
imipenem/cilastatin was evaluated for clinical and micro-
biologic responses by using a 2-sided 95% confidence
interval (CI) for the true difference in efficacy (tigecycline
minus imipenem/cilastatin) adjusted for the stratification
variable APACHE II score and corrected for continuity.
Noninferiority was concluded if the lower limit of the 2-
sided 95% CI was greater than or equal to -15%. For all
subpopulation analyses (eg, monomicrobial versus pol-
ymicrobial infection), an adjusted difference between
treatment groups with its 95% CI was calculated from a
generalized linear model with a binomial probability
function and an identity link (SAS®  Proc GENMOD).
Interaction effects were tested at the 0.10 level of signifi-
cance. With the planned sample size (n = 788) and an
evaluability rate of 50%, the trial had a power of at least
90% to determine the noninferiority of tigecycline com-
pared with imipenem/cilastatin.
Results
Eight hundred ninety-eight (898) patients were screened
for study participation at 96 sites in 17 countries in the
United States, Canada, Europe, Latin America, India, and
Asia from November 2002 to August 2004. Of these, 64
patients did not meet protocol requirements (Figure 1).
The remaining 834 patients were randomized in a 1:1
ratio to one of the two treatment regimens and repre-
sented the ITT population; however, 9 patients never
received study drug. Accordingly, 825 patients (413 tige-
cycline, 412 imipenem/cilastatin) comprised the mITT
(safety) population. The majority of the mITT population
(98%; 807 of 825) had clinical evidence of a complicated
intra-abdominal infection (clinical mITT population).
Within this latter cohort, 692 patients were clinically eval-
uable (clinically evaluable [CE] population). One hun-
dred thirty three (133; 16.1%) mITT patients (72
tigecycline, 61 imipenem/cilastatin) were not included in
the CE population for the following primary reasons
(patients could have been excluded for more than one rea-
son): no clinical evaluation at the test-of-cure visit (n =
Table 1: Demographic and baseline medical characteristics (ME population)
Tigecycline N = 247 Imipenem/Cilastatin N = 255
Mean ± SD age, years 42.9 ± 18.0 43.1 ± 17.6
Sex, n (%) male 173 (70.0) 166 (65.1)
Ethnic origin, n (%)
White 104 (42.1) 106 (41.6)
Black 16 (6.5) 25 (9.8)
Asian 30 (12.1) 30 (11.8)
Hispanic 54 (21.9) 44 (17.3)
Other 43 (17.4) 50 (19.6)
Mean ± SD weight, kg 70.3 ± 15.7 69.3 ± 15.9
Mean ± SD creatinine clearance, mL/min 94.2 ± 35.3 94.3 ± 34.1
Mean ± SD therapy duration, days 8.1 ± 2.8 7.9 ± 2.7
Mean APACHE II score 5.6 5.5
Primary intra-abdominal diagnosis, n (%)
Complicated appendicitis 152 (61.5) 145 (56.9)
Perforation of intestine 21 (8.5) 23 (9.0)
Complicated diverticulitis 17 (6.9) 25 (9.8)
Intra-abdominal abscess 17 (6.9) 17 (6.7)
Peritonitis 14 (5.7) 16 (6.3)
Gastric/duodenal perforation 13 (5.3) 10 (3.9)
Complicated cholecystitis 12 (4.9) 16 (6.3)
Other* 1 (0.4) 3 (1.2)
*Other diagnoses included infected hematoma, pelvic inflammatory disease, acute abdomen subocclusion, acute inflammatory abdomen, disease 
pelvic infectious, tubo-ovarian abscess, right tubal abscess, infected left subphrenic hematoma.BMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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47); entry criteria not met (n = 28); blind broken (n = 22);
and received more than 1 dose of a nonstudy antibiotic
after pretherapy culture (n = 12). From the mITT popula-
tion, 621 of 825 (75%) patients had a pretherapy isolate
isolated and comprised the m-mITT population. A total of
502 m-mITT patients (247 tigecycline, 255 imipenem/cil-
astatin) met both clinical evaluability criteria and had a
pretherapy isolate isolated from an intra-abdominal
source (ME population).
Demographic/baseline medical characteristics
The demographic characteristics for the 502 ME patients
were comparable between the two treatment groups
(Table 1). The study population was of mixed racial/eth-
nic background with whites (41.8%) and Hispanics
(19.5%) represented most often. There was a predomi-
nance of men (67.5%) and the mean age of enrolled
patients was 43 years old. Complicated appendicitis
(59%) was the most common intra-abdominal infection
diagnosis, followed by perforated intestine (8.8%) and
gastric/duodenal ulcer (4.6%). No significant differences
between the treatment groups were observed in the
number or types of infections diagnosed at baseline. The
severity of intra-abdominal illness was similar in each
treatment group (mean APACHE II score was ~5.7).
Clinical efficacy
For the ME population, clinical cure rates were 80.6% for
tigecycline and 82.4% for imipenem/cilastatin (95% CI -
9.0, 5.4; Table 2). Corresponding clinical cure rates for the
m-mITT population were 73.5% and 78.2% (95% CI -
11.8, 2.3), respectively. For both the ME and m-mITT pop-
ulations, tigecycline was efficacious and statistically non-
inferior to imipenem/cilastatin. Multiple subgroup
analyses of clinical responses (eg, age, sex, race, geo-
graphic location) found consistently efficacious clinical
responses between the treatment groups. No significant
treatment differences in clinical response were observed
between the two treatment groups when patients were
stratified by the number of isolated baseline isolates
(Table 2). For the ME population, tigecycline had a 89.8%
clinical cure rate at the test-of-cure visit for monomicro-
bial infections and a 75.3% clinical cure rate for pol-
ymicrobial infections. Similar rates were observed for
recipients of imipenem/cilastatin (88.5% and 78.1%,
respectively).
For complicated appendicitis, the most frequent diagno-
sis, clinical cure rates at the test-of-cure visit was 84.2% for
tigecycline and 86.2% for imipenem/cilastatin (Table 3).
In both treatment groups, lower clinical cure rates (≤72%)
were observed in patients who had intra-abdominal
abscess, complicated diverticulitis, or intestinal perfora-
tion (Table 3). Overall, there were no significant differ-
ences in clinical cure rates between tigecycline and
imipenem/cilastatin based on primary intra-abdominal
diagnosis. A total of 14 tigecycline- and 27 imipenem/cil-
astatin-treated patients in the ME population had a posi-
tive pretherapy blood culture. Clinical cure in patients
with bacteremia was reported for 71.4% of tigecycline and
74.1% of imipenen/cilastatin recipients.
Table 2: Clinical cure rates at test-of-cure visit
Tigecycline Imipenem/cilastatin Difference 
Tigecycline-
Imipenem/
cilastatin
Test for 
Noninferiority
Test for 
Differences
Population N % (95% CI) N % (95% CI) % (95% CI) P value
CE 282/341 82.7 (78.3, 86.6) 295/351 84.0 (79.8, 87.7) -1 (-7.2, 4.5) <0.0001 0.70
Overall -1 (-6.9, 4.2)*
c-mITT 303/408 74.3 (69.7, 78.4) 317/399 79.4 (75.1, 83.3) -5 (-11.2, 0.0) <0.0001 0.00
Overall -5 (-11.0, 0.0)
ME 199/247 80.6 (75.1, 85.3) 210/255 82.4 (77.1, 86.8) -1.8 (-9.0, 5.4) 0.0001 0.6892
Monomicrobial 80/89 89.9 (81.7, 95.3) 92/104 88.5 (80.7, 93.9) 1.4 (-8.7, 11.0)
Polymicrobial 119/158 75.3 (67.8, 81.8) 118/151 78.1 (70.7, 84.5) -2.8 (-12.6, 7.1)
Overall -1.7 (-8.4, 5.1)*
m-mITT 227/309 73.5 (68.2, 78.3) 244/312 78.2 (73.2, 82.7) -4.7 (-11.8, 2.3) 0.0019 0.1976
Monomicrobial 96/121 79.3 (71.0, 86.2) 109/128 85.2 (77.8, 90.8) -5.8 (-15.9, 4.3)
Polymicrobial 131/188 69.7 (62.6, 76.2) 135/184 73.4 (66.4, 79.6) -3.7 (-13.1, 5.9)
Overall -4.3 (-11.0, 2.5)*
*Adjusted difference and its 95%CI are calculated from a generalized linear model with a binomial probability function and an identity link.BMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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Microbiologic efficacy
For the ME population, eradication of intra-abdominal
isolates at the patient level was reported for 80.6% of tige-
cycline- and 82.4% of imipenem/cilastatin-treated
patients (95% CI -9.0, 5.4), indicating that tigecycline was
efficacious and statistically noninferior to imipenem/cil-
astatin (Table 4). No significant differences between the
treatment groups were found when eradication rates were
stratified by monomicrobial versus polymicrobial infec-
tion (Table 4).
Generally, eradication rates at the test-of-cure visit for the
most commonly isolated intra-abdominal isolates were
similar between the two treatment groups (Table 5). For E.
coli, the most commonly isolated aerobe, eradication rates
were 80.4% for tigecycline versus 83.5% for imipenem/
cilastatin. Corresponding eradication rates for Klebsiella
spp, the second most frequently isolated gram-negative
aerobe, were 87.1% and 85.7%, respectively. A total of 6
ESBL-producing E. coli and 7 ESBL-producing K. pneumo-
niae isolates were identified pretherapy. The majority of
these isolates were eradicated by tigecycline: 83% (5/6)
and 71% (5/7), respectively. Eradication rates for Bacter-
oides fragilis were 69.8% for tigecycline and 72.5% for
imipenem/cilastatin.
Pretherapy in vitro activity against baseline isolates for
tigecycline and imipenem/cilastatin are shown in Table 6.
The mean MIC90 for tigecycline against the most com-
monly isolated aerobes and anaerobes was ≤2.0 mg/L. No
pretherapy isolates displayed resistance to tigecycline
based on the provisional breakpoints used. Bacterial sus-
ceptibilities to tigecycline appeared to be consistent with
clinical responses.
Table 3: Clinical cure rate by baseline diagnosis (ME population) at test-of-cure visit
Tigecycline Imipenem/cilastatin Difference 
Tigecycline-Imipenem/
cilastatin
Clinical Diagnosis N % (95% CI) N % (95% CI) % (95% CI)
Complicated appendicitis 128/152 84.2 (77.4, 89.6) 125/145 86.2 (79.5, 91.4) -2.0 (-10.6, 6.7)
Perforation of the intestines 13/21 61.9 (38.4, 81.9) 15/23 65.2 (42.7, 83.6) -3.3 (-32.4, 26.2)
Complicated diverticulitis 12/17 70.6 (44.0, 89.7) 18/25 72.0 (50.6, 87.9) -1.4 (-32.0, 26.7)
Intra-abdominal abscess 11/17 64.7 (38.3, 85.8) 12/17 70.6 (44.0, 89.7) -5.9 (-37.6, 27.4)
Peritonitis 12/14 85.7 (57.2, 98.2) 15/16 93.8 (69.8, 99.8) -8.0 (-38.2, 20.5)
Complicated cholecystitis 11/12 91.7 (61.5, 99.8) 14/16 87.5 (61.7, 98.4) 4.2 (-29.4, 32.4)
Gastric and abdominal perforations 11/13 84.6 (54.6, 98.1) 10/10 100.0 (69.2, 100.0) -15.4 (-46.3, 21.3)
Other 1/1 100.0 (2.5, 100.0) 1/3 33.3 (0.8, 90.6) 66.7 (-42.3, 98.2)
Concomitant bacteremia 10/14 71.4 (41.9, 91.6) 20/27 74.1 (53.7, 88.9) -2.6 (-35.3, 25.4)
Table 4: Microbiologic response at the patient level (ME Population) at test-of-cure visit
Tigecycline Imipenem/cilastatin Difference 
Tigecycline-
Imipenem/
cilastatin
Test for 
Noninferiority
Test for 
Differences
Response N % (95% CI) N % (95% CI) % (95% CI) P value
Eradication 199/247 80.6 (75.1, 85.3) 210/255 82.4 (77.1, 86.8) -1.8 (-9.0, 5.4) 0.0001 0.6892
Persistence 39/247 15.8 (11.5, 20.9) 42/255 16.5 (12.1, 21.6)
Documented 4/39 10.3 (2.9, 24.2) 1/42 2.4 (0.1, 12.6)
Presumed 35/39 89.7 (75.8, 97.1) 41/42 97.6 (87.4, 99.9)
Superinfection 9/247 3.6 (1.7, 6.8) 3/255 1.2 (0.2, 3.4)
Overall -1.7 (-8.4, 5.1)*
*Adjusted difference and its 95%CI are calculated from a generalized linear model with a binomial probability function and an identity link.BMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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Safety and tolerability
Data from all patients in the mITT population (n = 825)
were analyzed for safety. The m-ITT population received a
median of 7 days of tigecycline or imipenem/cilastatin
treatment. Regardless of study drug causality, the
frequency and distribution of treatment-emergent adverse
events occurring in at least 3% of patients in either
treatment group were similar to those observed in the imi-
penem/cilastatin treatment group. The majority of these
adverse events were related to study medication (56%)
and were mild to moderate in intensity (94%). Digestive
system (56.9% vs 49.8%, P = 0.043), nausea (31.0% tige-
cycline, 24.8% imipenem/cilastatin; P = 0.052), vomiting
(25.7% tigecycline, 19.4% imipenem/cilastatin; P  =
0.037), and diarrhea (21.3% tigecycline, 18.9% imi-
penem/cilastatin;  P  = 0.435) were the most frequently
reported adverse events in both treatment groups. The
majority of patients in both treatment groups experienced
mild to moderate nausea and/or vomiting (94%). There
was no significant difference between the treatment
groups in the number of patients who required antiemetic
therapy for nausea and/or vomiting. No tigecycline-
treated patient has a positive Clostridium difficile toxin
assay, nor developed C. difficile associated diarrhea.
In the tigecycline group, infections (13.6% vs 7.5%, P =
0.006), hypoproteinemia (8.0% vs 4.1%, P = 0.028), and
dyspnea (6.8% vs 2.9%, P  = 0.014) were statistically
Table 5: Microbiologic response at the isolate level: selected baseline isolates at test-of-cure visit (ME population)
Tigecycline Imipenem/cilastatin
Isolate N MIC90 % (95% CI) N MIC90 % (95% CI)
Bacteroides fragilis 30/43 2.0 69.8 (53.9, 82.8) 29/40 0.5 72.5 (56.1, 85.4)
Citrobacter spp. 13/15 1.0 86.7 (59.5, 98.3) 5/7 0.5 71.4 (29.0, 96.3)
Clostridium spp. 16/19 1.0 84.2 (60.4, 96.6) 14/18 2.0 77.8 (52.4, 93.6)
Enterobacter spp. 6/8 1.0 75.0 (34.9, 96.8) 5/10 1.0 50.0 (18.7, 81.3)
Enterococcus faecalis (non-VRE) 10/16 0.25 62.5 (35.4, 84.8) 9/18 4.0 50.0 (26.0, 74.0)
Escherichia coli 135/168 0.5 80.4 (73.5, 86.1) 152/182 0.25 83.5 (77.3, 88.6)
Fusobacterium spp. 3/5 0.25 60.0 (14.7, 94.7) 6/7 0.25 85.7 (42.1, 99.6)
Klebsiella spp. 27/31 1.0 87.1 (70.2, 96.4) 36/42 0.25 85.7 (71.5, 94.6)
Peptostreptococcus spp. 6/10 0.12 60.0 (26.2, 87.8) 5/8 0.25 62.5 (24.5, 91.5)
Proteus spp. 5/10 4.0 50.0 (18.7, 81.3) 3/3 4.0 100.0 (29.2, 100.0)
Pseudomonas aeruginosa 13/18 32.0 72.2 (46.5, 90.3) 19/21 2.0 90.5 (69.6, 98.8)
Staphylococcus aureus (MRSA) 1/2 NA 50.0 (1.3, 98.7) 0/1 NA 0.0 (0.0, 97.5)
S. aureus (non-MRSA) 7/8 0.25 87.5 (47.3, 99.7) 3/4 0.12 75.0 (19.4, 99.4)
Streptococcus spp. 63/81 0.12 77.8 (67.2, 86.3) 46/67 0.12 68.7 (56.2, 79.4)
MRSA = methicillin-resistant Staphylococcus aureus; VRE = vancomycin-resistant enterococci.
NA = MIC90 values are not valid if the number of isolates is less than 10.
Table 6: MIC range, and MIC50 and MIC90 values of selected primary baseline isolates (ME population)
Tigecycline Imipenem/Cilastatin
Isolate n MIC range MIC50 MIC90 MIC range MIC50 MIC90
Bacteroides fragilis 83 0.06–16.0 1.0 2.0 0.12–4.0 0.25 0.5
Clostridium perfringens 12 0.06–2.0 1.0 2.0 0.12–0.25 0.12 0.25
Enterococcus faecalis (non-VRE) 32 0.06–0.25 0.12 0.25 1.0–4.0 1.0 4.0
Escherichia coli 350 0.06–1.0 0.25 0.50 0.12–1.0 0.12 0.25
Klebsiella pneumoniae 58 0.25–2.0 0.50 1.00 0.12–0.50 0.25 0.25
Pseudomonas aeruginosa 39 8.0–32.0 16.0 32.0 0.25–4.0 1.0 2.0
Staphylococcus aureus (MRSA) 3 0.12–0.25 NA NA 0.12–32.0 NA NA
S. aureus (non-MRSA) 12 0.12–0.50 0.25 0.25 0.12–0.12 0.12 0.12
NA = MIC50 and MIC90 values are not valid if the number of isolates is less than 10.
MRSA = methicillin-resistant Staphylococcus aureus.
VRE = vancomycin-resistant enterococci.BMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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higher than in the imipenem/cilastatin treatment group.
The difference in infection rates between the treatment
groups was primarily due to the development of second-
ary wound infections. No apparent trends or risk factors
were identified in the development of secondary wound
infections in either treatment group.
One hundred forty-five (145) patients had one or more
serious adverse events during the study (81 [19.6%]
tigecycline, 64 [15.5%] imipenem/cilastatin) (P = 0.143).
The most frequently reported serious adverse events were
abnormal healing (14 tigecycline, 6 imipenem/cilastatin),
abscess (10 tigecycline, 8 imipenem/cilastatin), and infec-
tion (10 tigecycline, 9 imipenem/cilastatin). Significantly
more patients treated with tigecycline (6 [1.5%]) versus
none treated with imipenem/cilastatin reported pneumo-
nia as a serious adverse event (P = 0.031).
Adverse events were the primary reason for early with-
drawal of study drug. A total of 27 (6.5%) tigecycline- and
15 (3.6%) imipenem/cilastatin-treated patients discon-
tinued treatment prematurely because of an adverse event
(P = 0.080). A total of 10 (2.5%) tigecycline- and 4 (1.0%)
imipenem/cilastatin-treated patients stopped therapy pre-
maturely secondary to either nausea (6 tigecycline, 2 imi-
penem/cilastatin) and/or vomiting (4 tigecycline, 2
imipenem/cilastatin). There were no significant differ-
ences between treatment groups in any single adverse
event leading to the discontinuation of study drug.
Twenty-nine (29) patients died during the study: 17
patients in the tigecycline group and 12 patients in the
imipenem/cilastatin treatment group. Only two of the
deaths, both in the tigecycline group, were considered by
the investigators to be possibly related to study drug sec-
ondary to treatment failure. The first patient was a 78 year
old female who received tigecycline for one week. Two
days following discontinuation of therapy the patient
developed septic shock; she died one day later. The second
patient, a 23 year old female, presented with sepsis and
received 3 days of tigecycline therapy. On day 3 she was
found to have pneumonia and progressed to multiple
organ failure with sepsis and died the same day.
Few clinically important or unexpected changes in any
routine hematologic or serum chemistry tests, vital signs,
or ECG data were associated with the use of tigecycline or
imipenem/cilastatin. However, significantly more
patients treated with imipenem/cilastatin (312/410,
76.1%) than those treated with tigecycline (275/408,
67.4%) had 1 or more laboratory findings of potential
clinical importance (P  = 0.007). Imipenem/cilastatin-
treated patients had significantly lower serum potassium
(≤3 mmol/L; P = 0.004), phosphorus values (≤ 0.8 mmol/
L; P < 0.001), and lymphocytes values (≤0.6 cells × 109/L;
P < 0.001). Yet, significantly more patients treated with
tigecycline than those treated with imipenem/cilastatin
had clinically significant hypoproteinemia (≤35 g/L; P =
0.001). No significant changes in QTc interval were
observed in either treatment group at any time point.
Discussion
This large trial demonstrated that tigecycline (100 mg ini-
tial dose, followed by 50 mg q12 hours) is effective for the
treatment of hospitalized adult patients with complicated
intra-abdominal infections. For patients with proven bac-
terial infections, clinical cure rates were 80.6% for tigecy-
cline versus 82.4% for imipenem/cilastatin at the test-of-
cure visit, demonstrating that tigecycline met the statisti-
cal criteria for noninferiority compared with the carbap-
enem regimen. We also observed that tigecycline's clinical
efficacy was similarly effective in patients who had either
monomicrobial versus polymicrobial infection, as well as
across the variety of anatomical infections encountered.
While many previous studies have reported a higher per-
centage of polymicrobial infection from intra-abdominal
sites, the lower rates seen with tigecycline may be
explained by a larger proportion of patients with appendi-
citis as the source of infection. Overall, the efficacy of tige-
cycline was consistent among all predefined populations
analyzed (m-mITT, c-mITT, CE) and consistent across dif-
ferent species of infecting bacteria.
This large study extends the findings of two other studies
that evaluated tigecycline's efficacy in the treatment of
complicated intra-abdominal infections. In a small, open-
label, phase 2 tigecycline trial of 66 hospitalized patients
with primarily perforated appendicitis, cure rates at the
test-of-cure visit and end-of-treatment visit were 67% and
76%, respectively [17]. A similarly designed phase 3 trial
reported comparable clinical cure rates for the m-mITT
cohort of 86.6% (279/322) for tigecycline compared with
84.6% (270/319) for imipenem/cilastatin therapy [18].
The current trial demonstrated that tigecycline was effec-
tive at eradicating commonly encountered aerobic and
anaerobic intestinal bacteria. Overall eradication rates
were nearly identical in the two treatment groups: 80.6%
after tigecycline therapy compared with 82.4% in the imi-
penem/cilastatin group. More than 80% of E. coli and
Klebsiella spp. (the two most frequently isolated gram-neg-
ative aerobes) were eradicated by tigecycline, followed by
78% of Streptococcus spp, and 70% of B. fragilis. Compara-
ble eradication rates were observed following imipenem/
cilastatin therapy, further establishing that tigecycline was
at least as effective as the standard carbapenem regimen.
These data support in vitro observations that tigecycline
has broad-spectrum activity against common isolates
found in intra-abdominal infections [8-16]. While the eti-
ologic role of P. aeruginosa remains unclear in patientsBMC Infectious Diseases 2005, 5:88 http://www.biomedcentral.com/1471-2334/5/88
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with community-acquired intra-abdominal infections,
tigecycline lacks reliable in vitro activity against this
organism [8,9,11,13] despite a 72% eradication rate in
this study.
Because few resistant isolates were isolated in the current
trial, we could not conclusively establish the in vivo effec-
tiveness of tigecycline against organisms that typically
convey resistance (eg, E. faecalis, methicillin-sensitive and
-resistant  S. aureus, ESBL-producing Enterobacter  spp.).
However, tigecycline successfully eradicated the majority
(77%) of the 13 ESBL-producing E. coli and K. pneumoniae
that were recovered from patients with cIAI. These limited
data confirm tigecycline's documented in vitro activity
against many gram-positive and gram-negative bacterial
isolates that typically are resistant [11,16,19].
Both tigecycline and imipenem/cilastatin were well toler-
ated in the current trial, with a similar frequency and dis-
tribution of treatment-emergent adverse events. Nausea,
vomiting, and diarrhea were the most frequently reported
adverse events in both the tigecycline and imipenem/cil-
astatin treatment groups. Although the individual adverse
events of nausea and vomiting occurred at higher rates
after tigecycline compared with imipenem/cilastatin ther-
apy, only the incidence of vomiting was found to be sig-
nificantly higher in tigecycline recipients. Furthermore,
the majority of nausea/vomiting events in both treatment
groups were of mild to moderate intensity (94%). Sup-
porting this fact, these gastrointestinal adverse events
rarely led to early discontinuation of therapy in either
treatment group (<2%) and there was no difference in the
number of patients requiring interventional antiemetic
therapy between the tigecycline and imipenem/cilastatin
groups. It is also noteworthy that tigecycline mono-
therapy was not associated with the development of C. dif-
ficile diarrhea. These findings support previous safety data
from phase 2 and 3 studies [20-25].
Conclusion
Tigecycline is an effective and well-tolerated monotherapy
option for the treatment of patients with complicated
intra-abdominal infections, with comparable efficacy to
imipenem/cilastatin. Because of the rising rates of antibi-
otic-resistant bacteria, both in the community and hospi-
tal settings, there remains a need for new antibiotic
options. According, tigecycline is a promising new mono-
therapy when empiric coverage is needed against both
gram-positive and non-pseudomonal gram-negative bac-
teria, including improved in vitro activity against certain
resistant isolates.
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